A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Recruiting · NCT06528301 · Registry updated 2026-10-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-10-07 | NCT06528301 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Umoja Biopharma | 4 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope | Duarte | United States | 238 |
| Fred Hutch Cancer Center | Seattle | United States | 12 |
| Royal North Shore Hospital | Saint Leonards | Australia | 30 |
| St. Vincent's Hospital Melbourne | Fitzroy | Australia | 12 |
| START Midwest | Grand Rapids | United States | 79 |
| The David and Etta Jonas Center for Cellular Therapy | Chicago | United States | 1 |
| University of Cincinnatti Medical Center | Cincinnati | United States | 1 |
| University of Nebraska Medical Center | Omaha | United States | 1 |
| Washington University School of Medicine/Siteman Cancer Center | St Louis | United States | 1 |